Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Aldesleukin (Proleukin) patient drug information (Chemocare)
- Aldesleukin (Proleukin) patient drug information (UpToDate)
History of changes in FDA indication
- 1992-05-05: Initial approval for treatment of adults (>18 years old) with metastatic renal cell carcinoma. (Based on Fyfe et al. 1995)
- Uncertain date: Approved for the treatment of adults with metastatic melanoma. (Based on Atkins et al. 1999)
History of changes in EMA indication
- 1989-07-03: EURD
History of changes in PMDA indication
- 2021-06-23: New indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for neuroblastoma.
Also known as
- Code name: ILT-101
- Generic names: Interleukin-2, IL-2
- Brand names: Macrolin, Proleukin, Teceleukin